Shares of Soleno Therapeutics (SLNO) are up 35% or $17.03 at $66.00 after the stock resumed trading. Shares had been halted ahead of the company announcement of FDA approval of VYKAT XR to treat hyperphagia.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue